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Abstract
Background: Irinotecan-loaded drug-eluting beads represent a novel drug delivery method that allows
for the locoregional delivery of irinotecan to colorectal liver metastases (CRLM). The method has shown
impressive response rates. However, the pathological response to this treatment has not previously been
demonstrated.
Methods: Patients with easily resectable CRLM were treated with drug-eluting beads delivering irinote-
can (DEBIRI) 4 weeks prior to resection. Pathological tumour response was graded using a validated
system. The intraoperative detection of previously unidentified disease allowed for the assessment of
pathological responses directly attributable to bead treatment.
Results: In Patient 1, segmental embolization of the target lesion in segment VIII resulted in 100%
necrosis (0% viability). An untreated lesion in segment IV was found to be 30% viable. In Patient 2,
subsegmental embolization of the target lesion in segment VI resulted in 60% necrosis and 40% fibrosis
(0% viability). An untreated lesion in segment VI remained 60% viable. In Patient 3, lobar embolization of
the target lesion in segment II resulted in 0% viability. Two further lesions within the treated hemiliver, both
with 0% viability, and one lesion in the untreated hemiliver with 45% viability were discovered at
laparotomy.
Conclusions: This series demonstrates the effectiveness of DEBIRI in the treatment of CRLM. High
rates of tumour destruction are possible, even with the proximal lobar administration of DEBIRI. Lobar
administration appears to be an appropriate method of delivery for integration into future therapeutic
regimens.
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Introduction
The majority of patients with colorectal cancer will develop
metastases and approximately one quarter are found to have
distant metastases at the time of presentation. Surgical resection is
the only potentially curative option for these patients and results
in reported 5-year survival of around 40%, but is an option for
only a minority of patients.1–13 Response to chemotherapy corre-
lates with resection rate14 and it seems logical that patients with
unresectable liver-limited disease, regardless of its extent and dis-
tribution, should be treated with the most aggressive systemic
induction or conversion therapy and that this strategy should
represent the primary course of treatment with the purpose of
bringing these patients to potentially curative resection. Resecta-
bility rates after chemotherapy for initially unresectable disease
vary widely, with recently reported regimens achieving conversion
rates approaching 60%.14 Attempts to bring unresectable disease
to resection are worthwhile and result in overall 5-year survival
rates comparable with those in patients found to be resectable at
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presentation.15 The UK National Institute for Clinical Excellence
(NICE) currently recommends the use of regimens based on
folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin
(FOLFOX) with or without cetuximab as first-line therapy in all
patients with non-resectable disease, and suggests that irinotecan-
based (FOLFIRI) regimens should be used as second-line therapy
after the failure of first-line treatment, although the efficacy of
FOLFIRI is comparable with that of FOLFOX in the setting of
metastatic disease.16 Intensive triplet chemotherapy with FOL-
FOXIRI has been compared with FOLFIRI alone in a Phase III
randomized controlled trial.17 Response rates were higher after
FOLFOXIRI, which resulted in a secondary resection rate of 36%
in patients with liver-limited disease compared with 12% in those
treated with standard FOLFIRI (P = 0.017). However, off-target
toxicity (mainly manifesting as severe diarrhoea) was high and
thus double-agent cytotoxic therapy remains the first-line
treatment of choice.
The precise role of true neoadjuvant chemotherapy in the
management of resectable disease remains controversial. The
European Organization for Research and Treatment of Cancer
(EORTC) 40983 Phase III trial assessed perioperative chemo-
therapy by randomizing patients to perioperative FOLFOX and
surgery or to surgery alone and demonstrated a significantly
improved 3-year progression-free survival rate in the perio-
perative chemotherapy arm,18 although this did not translate
to improved longterm outcome.19 Despite these negative long-
term findings, the majority of patients with high-risk colorectal
liver metastases (CRLM), as indicated by synchronous pre-
sentation, bilobar disease, the presence of three or more metas-
tases, metastases measuring >5 cm or high preoperative carci-
noembryonic antigen (CEA) levels (>100 ng/ml), continue to
receive perioperative chemotherapy irrespective of their
initial resectability20 on the premise that this will result in the
destruction of occult disease, allow a test of biology in patients
in whom progression despite chemotherapy signifies poor
biology, as well as reduce lesion size and thereby improve
resectability.
Previous work has demonstrated impressive response rates fol-
lowing the delivery of chemotherapy by hepatic arterial pump.21
However, the invasiveness of pump insertion and relatively high
rates of complications have limited the adoption of this tech-
nique.22 Drug-eluting beads [marketed as DC Bead® in Europe
(Biocompatibles UK Ltd, Farnham, UK)] are compressible beads
produced from polyvinyl alcohol hydrogel that can be loaded
with irinotecan. This method offers a theoretical advantage over
hepatic arterial infusion because delivery is simplified (emboliza-
tion and chemotherapy are combined, with no need for a pump)
and it offers the potential to add locoregional irinotecan to sys-
temic FOLFOX with the aim of achieving response rates compa-
rable with those seen after FOLFOXIRI whilst minimizing
morbidity. In the single-arm, prospective Phase II safety and effi-
cacy PARAGON II study, patients with easily resectable CRLM
were given a single neoadjuvant treatment 4 weeks prior to
surgery with DC Irinotecan Bead, a next-generation investiga-
tional product in which the embolic bead is preloaded with a
standardized dose of irinotecan by the manufacturer (Biocom-
patibles UK Ltd). The primary endpoint was tumour resectability;
secondary endpoints included the safety of transarterial
chemoembolization (TACE) and post-TACE surgery, radiologic
response [using RECIST (response evaluation criteria in solid
tumours) and assessment of necrosis] and pathological tumour
response.23
In a minority of patients who come to hepatic resection, pre-
operative imaging fails to detect all disease identifiable at
laparotomy.24 In the PARAGON II study, three patients were
found to have intrahepatic disease that was not identified preop-
eratively and thus was not treated with drug-eluting beads deliv-
ering irinotecan (DEBIRI). The aim of the present study was to
investigate findings in those patients in the PARAGON II trial in
whom both treated and untreated lesions were identified in order
to assess the pathological response directly attributable to
treatment with DEBIRI-TACE.
Materials and methods
Recruitment
The PARAGON II trial (Fig. 1) was approved by regulatory
authorities and local ethics committees in the UK, France, Spain
and Austria and registered at clinicaltrials.gov (NCT00844233).
All patients were fully staged using computed tomography (CT) of
the chest, abdomen and pelvis, magnetic resonance imaging
(MRI) with liver-specific contrast and positron emission tomo-
graphy (PET)-CT. All patients recruited had easily resectable
CRLM as defined by the specialist hepatopancreatobiliary (HPB)
Patient with easily resectable 
colorectal liver metastases
Single treatment with
DEBIRI-TACE
Resection
Follow-up
4 weeks
Figure 1 CONSORT (consolidated standards of reporting trials)
diagram of PARAGON II study. DEBIRI-TACE, drug-eluting beads
delivering irinotecan transarterial chemoembolization
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multidisciplinary team (MDT), with <60% liver tumour replace-
ment. It was the opinion of the MDT that these patients did not
require neoadjuvant chemotherapy within the routine standard
of care. All patients had undergone complete resection of
the primary tumour without gross or microscopic evidence of
residual disease (R0), and had not been previously exposed to
irinotecan-containing chemotherapy.
Embolization procedure
Embolization was performed by an experienced interventional
radiologist (EO’G or CK) and started with diagnostic angiography
to adequately define hepatic arterial anatomy and ensure no ext-
rahepatic shunting. Particular attention was paid to ensure the
catheter tip had passed beyond the cystic artery to avoid chem-
oembolization of the gallbladder. Treatment consisted of a
nominal dose of 2 ml of DC Bead® of 100–300 mm in diameter
containing 200 mg of irinotecan (PARAGON Bead®; Biocompati-
bles UK Ltd), mixed in non-ionic contrast media. Initially, very
selective embolization was performed and beads were delivered
directly to the subsegment containing the tumour. As experience
accumulated, a more proximal catheter placement into the right
or left hepatic artery was used. Irinotecan-loaded beads were
delivered slowly to near stasis. Patient analgesia was provided
using a combination of paracetamol, diclofenac, intra-arterial
lidocaine and post-procedural opiate patient-controlled analgesia
(PCA).
Surgical resection
Four weeks after embolization, patients underwent repeat CT of
the chest, abdomen and pelvis followed by surgical resection
(Table 1). All patients underwent open resection performed by an
experienced hepatobiliary surgeon. Laparotomy was performed
and extrahepatic abdominal disease excluded by full inspection.
Intraoperative ultrasound (IOUS) was routinely performed to
guide surgical planning. Low-volume anaesthesia was used with
the aim of maintaining a central venous pressure of <5 mmHg.
Liver parenchyma was transected with the Cavitron ultrasonic
surgical aspirator (CUSA®; Valleylab, Inc., Boulder, CO, USA).
Intermittent vascular inflow occlusion was used at the discretion
of the operating surgeon.
Pathological examination
Following resection, surgical specimens were fixed in formalin
and macroscopically dissected to produce paraffin-embedded
blocks. Tissue was sampled from the centre, mid-part and periph-
ery of the tumour, the tumour and adjacent liver parenchyma, and
the tumour and resection margin. After sectioning, specimens
were stained with haematoxylin and eosin and reviewed by an
experienced hepatobiliary pathologist (MT) and assessed accord-
ing to the UK Royal College of Pathologists Liver Resection Stand-
ard Dataset. Slides from each block were reviewed, and tumour
response graded using the method of Rubbia-Brandt et al.25
Briefly, the amount of residual cancer was assessed semi-
quantitatively by estimating the proportion of residual cancer
cells, necrotic tissue and fibrosis in relation to the total area of
cancer.
Results
Patient 1
A 68-year-old, White man was referred to the regional specialist
hepatobiliary MDT and recruited to the PARAGON II study.
Angiography at the time of embolization demonstrated a
hypovascular lesion in segment VIII, and 1 ml of DC Irinotecan
Bead was administered via the segment VIII segmental artery to
almost complete stasis. The procedure was well tolerated and the
patient was discharged 48 h after embolization. At laparotomy,
IOUS demonstrated the previously identified and treated lesion in
segment VIII, as well as a second untreated lesion in segment IV.
Both were treated with uneventful non-anatomical resection.
The treated lesion in segment VIII had a longest diameter of
25 mm and showed no residual tumour and 100% replacement
with necrotic tissue. By contrast, the untreated lesion in segment
IV (longest diameter: 25 mm) demonstrated 30% residual
tumour, 40% necrosis and 30% fibrosis (Fig. 2).
Patient 2
A 40-year-old, White man was referred to the regional specialist
hepatobiliary MDT with a suspicious liver lesion. Imaging with
MRI and PET-CT demonstrated no other intra- or extrahepatic
disease and the patient was recruited to the PARAGON II study.
Angiography confirmed a single lesion supplied by the segment
VI artery, which was treated by distal embolization with 0.5 ml of
DC Irinotecan Bead. The procedure was well tolerated and the
patient was discharged 24 h after embolization. At laparotomy
IOUS demonstrated the previously identified and treated lesion in
Table 1 Summary of patient treatment
Time from primary CRC surgery
to diagnosis of CRLM
Initial CT findings Dose of
DEBIRI-TACE
Time from DEBIRI-TACE to
resection
Patient 1 36 months Single lesion in segment VIII 100 mg 28 days
Patient 2 24 months Single lesion bordering segments
VI and VII
50 mg 28 days
Patient 3 12 months Single lesion bordering segments II
and IVa
130 mg 35 days
CRC, colorectal cancer; CRLM, colorectal liver metastasis; CT, computed tomography; DEBIRI-TACE, drug-eluting beads delivering irinotecan
transarterial chemoembolization.
HPB 73
HPB 2013, 15, 71–77 © 2012 International Hepato-Pancreato-Biliary Association
segment VI, as well as a second previously unidentified lesion in
the same segment, both of which were easily resected.
Pathological examination showed the lesion in segment VI seen
on CT and targeted with DC Irinotecan Bead had a longest diam-
eter of 15 mm, with no evidence of viable tumour, 60% necrosis
and 40% fibrosis (Fig. 3). By contrast, the untreated lesion in
segment VI (longest diameter: 14 mm) demonstrated 60%
residual tumour, 30% necrosis and 10% fibrosis.
Patient 3
A 63-year-old, White man was found to have a suspicious liver
lesion on CT and referred to the specialist HPB MDT. Preopera-
tive imaging identified a lesion on the border between segments II
and IVa with a longest diameter of 17 mm. The patient underwent
embolization and was treated with 1.3 ml of DC Irinotecan Bead
delivered in a lobar fashion via the left hepatic artery until partial
occlusion of the left subsegmental arteries was achieved. The
patient developed post-embolization syndrome (reported in 10%
of patients), with transient abdominal pain and nausea, but no
change in white cell count or liver function tests (Table 2). The
patient made a rapid recovery and was discharged home the fol-
lowing day.
On CT prior to surgery, the target lesion was found to have
shrunk to a longest diameter of 10 mm (a 41.2% reduction, indi-
cating a partial response according to RECIST criteria). However,
on imaging a second tumour in segment II (within the lobar
treatment zone) was clearly identified. Radiological assessment
suggested this lesion was 100% necrotic. Retrospective review of
the initial staging imaging showed no evidence of this lesion prior
to treatment with DEBIRI.
Figure 2 Preoperative imaging in Patient 1 showing a small 25-mm colorectal liver metastasis in segment VIII on (a) computed tomography
(CT), (b) contrast-enhanced magnetic resonance imaging and (c) positron-emission tomography-CT. No other disease was identified on
preoperative imaging
Figure 3 Histopathology in Patient 2 showing (a) targeted and (b) non-targeted colorectal liver metastasis. The treated lesion shows an
absence of viable tumour, with complete replacement with necrotic tissue. In (a), the irinotecan beads are clearly visible within the
vasculature. By contrast, the untreated lesion (b) shows islands of viable cells with minimal necrosis and fibrosis. (Haematoxylin and eosin
stain; original magnification ¥20)
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During surgery, IOUS detected two further lesions. One, in
segment III, had been treated by lobar infusion. The second intra-
operatively detected lesion was in segment VII and had not been
treated by DC Irinotecan Bead.
Postoperative examination of all four resected tumours showed
varying degrees of response. All three lesions in the left hemiliver,
which had been treated with DC Irinotecan Bead, demonstrated
the absence of viable tumour and 100% replacement with fibrotic
or necrotic tissue; these included the original target lesion in seg-
ments II and IVa, the second lesion in segment II that had been
inadvertently treated and was identified after treatment with DC
Irinotecan Bead but before resection, and the lesion in segment III
that had been intraoperatively identified and inadvertently
treated. By contrast, the lesion in segment VII, which was outwith
the zone covered by DC Irinotecan Bead treatment, demonstrated
45% residual tumour, 50% necrosis and 5% fibrosis.
Discussion
Findings in these three patients offer further evidence of the effec-
tiveness of DEBIRI for the treatment of hepatic metastases of
colorectal cancer. The DC Bead loaded with irinotecan is CE
(Conformité Européenne)-marked in Europe for the treatment of
metastatic colorectal cancer. LC Bead® does not yet have market
approval in the USA for use in combination with irinotecan, but is
used in US Food and Drug Administration-approved investiga-
tional clinical trials and has shown impressive results in both
chemo-naïve and heavily pretreated unresectable patients.26,27 An
international registry reported response rates of 66% at 6 months
and 75% at 12 months in 55 patients who had failed first- and
second-line systemic therapy for metastatic colorectal cancer and
were treated with DC Bead® with irinotecan. In a further prospec-
tive study of 75 patients with liver-only metastatic colorectal
cancer randomized to FOLFIRI or irinotecan beads, patients
treated with beads showed a statistically significant improvement
in median survival over those treated with chemotherapy (22
months versus 15 months; P = 0.03).28 However, the safety of this
treatment in a true neoadjuvant setting and the degree of patho-
logical response directly attributable to DEBIRI has not previously
been demonstrated. Pathological tumour response was chosen as
a surrogate marker for potential longterm benefit as it has been
clearly demonstrated that patients who exhibit a good pathologi-
cal response to chemotherapy have better overall survival. Blazer
et al.29 found that patients treated with preoperative chemo-
therapy who demonstrated fewer viable tumour cells on post-
resection examination had much better longterm outcomes. Only
9% of patients were found to have no viable tumour, whereas 33%
had tumours with viability of >50%. Five-year survival was 75%
in those with complete tumour destruction and 33% in patients
with tumours with viability of >50% (P = 0.007).29
Metastatic colorectal cancer often presents with a multi-focal
liver-dominant pattern. In this setting, targeted embolization is
not feasible, but lobar administration may be an option. At the
beginning of the PARAGON II study, selective embolization
was performed to deliver maximum treatment to target lesions.
However, as experience of the procedure accumulated, a more
proximal lobar delivery was used. The present report includes a
patient with undetected disease that was not directly targeted by
DEBIRI, but was located in a treated hemiliver. This patient was
also found to have a further undetected lesion in an untreated
lobe. This allowed for further comparison among three lesions
which were, respectively, directly targeted with DEBIRI, treated
with DEBIRI using lobar infusion, and non-treated.
Patient 1 underwent segmental embolization. At laparotomy,
two distinct lesions were resected, including one from within
the treated segment and one from an untreated segment. The
difference in viable tumour (0% versus 30%) was stark and sug-
gests that the lack of viable tumour seen within the post-
treatment specimen is directly attributable to DEBIRI treatment.
An indirect effect of DC Irinotecan Bead on the untreated
segment cannot be completely ruled out as the patient received
100 mg of irinotecan with the beads. However, pharmacokinetic
modelling has suggested that systemic exposure after treatment
with DEBIRI is low and thus this seems unlikely.27 A similar
pattern was observed in Patient 2, in whom targeted delivery of
irinotecan led to complete tumour destruction, whereas the
non-targeted lesion retained a large proportion of viable tumour
(0% versus 60%). Although the non-targeted lesion was located
in the treated segment, embolization was very distal and the
second lesion was not detected on angiography and thus is
unlikely to have been sited within the treatment zone. In Patients
1 and 2, the treated and untreated lesions were of comparable
size. This also means it is unlikely that the varying degrees of
viable tumour were attributable to anatomical variation, such as
Table 2 Results of peri-procedural blood tests in Patients 1–3
Pre-
DEBIRI-TACE
Post-
DEBIRI-TACE
Pre-
resection
Patient 1
WCC, 109/l 8.1 8.4 7.7
AST, U/l 21 97 147
ALP, U/l 163 235 457
Patient 2
WCC, 109/l 5.9 7.8 5.1
ALT, U/la 17 18 22
ALP, U/l 77 69 98
Patient 3
WCC, 109/l 5.5 9.6 5.9
AST, U/l 37 34 34
ALP, U/l 54 46 64
aRoutine laboratory profile changed from AST to ALT prior to this patients
treatment.
DEBIRI-TACE, drug-eluting beads delivering irinotecan transarterial
chemoembolization; WCC, white cell count; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase.
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when the blood supply to a larger lesion is inadequate to main-
tain tumour viability.
In Patient 3, the radiological appearance of a lesion after
embolization suggests an inherent change in the structure of that
lesion. Post-resection analysis demonstrated that this lesion had
75% necrosis and 25% fibrosis. Therefore, it seems likely that the
initial effect of the delivery of DC Irinotecan Bead in this lesion
was mediated predominantly by occlusion of the blood supply to
the tumour rather than the effect of the irinotecan because
chemotherapy-associated change seems to be represented by
fibrotic involution rather than necrosis.30 Interestingly, all the
lesions within the treated lobe showed 0% viable tumour. By
contrast, the untreated lesion in segment VII demonstrated a large
amount of viable tumour (45%) and a very low amount of fibrosis
(5%), as would be expected in a chemo-naïve lesion.
The large amount of viable tumour observed in lesions sup-
plied by arterial flow proximal to the point of bead release and the
absence of tumour in previously unidentified lesions targeted by
lobar embolization support the oncologic rationale for very proxi-
mal ‘whole-lobe’ embolization. These results suggest that unde-
tected micrometastatic lesions within a lobar embolization zone
can be treated as effectively as lesions that are identified preopera-
tively and more selectively embolized. This finding is important
for the design of future trials. Over 60% of patients who undergo
liver surgery with curative intent will experience recurrence
within 2 years of resection31 because of previously undetected
micrometastatic disease. Lobar treatment with DC Irinotecan
Bead may be sufficient to destroy these micrometastases and
thereby reduce postoperative recurrence.
The impressive pathological response rates reported in this
series, in which multiple treated lesions showed no viable tumour
cells, may raise questions about the utility of surgery in this
setting. If disease can be adequately treated by chemotherapy, is it
necessary to resect? Currently, surgery remains the reference
standard treatment, even after a complete radiological response
has been achieved. Lesions that are not identified in preoperative
imaging are often detected at laparotomy by IOUS and these
lesions can be surgically resected at the time of detection, resulting
in low rates of local disease recurrence.32 A complete pathological
response also remains a pathological diagnosis and 80% of lesions
that show a complete radiological response are found to contain
viable tumour.33 Thus it is likely that even in lesions that show a
complete radiological response, a number of viable tumour cells
remain. Advances in imaging, including the use of PET-CT,34 have
failed to accurately identify patients who have achieved a complete
pathological response and this diagnosis therefore continues to
rely on microscopic examination.
Conclusions
This patient series demonstrates the effectiveness of the investiga-
tional product DC Irinotecan Bead in the treatment of CRLM.
High rates of tumour destruction are possible, even with the
proximal lobar delivery of irinotecan-loaded beads. Lobar admin-
istration appears to be an appropriate method of delivery if this
treatment is to be integrated into future therapeutic regimens
with the aim of reducing occult micrometastatic disease.
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